VOR BIOPHARMA DL-,0001

Vor Bio has appointed David Zaccardelli to its board of directors. Zaccardelli was most recently CEO of Verona Pharma until its acquisition by Merck in October 2025; there he led Phase‑3 programs to completion, secured FDA approval for Ohtuvyre and raised over $1 billion in capital. He previously served as CEO of Dova Pharmaceuticals and held leadership roles at United Therapeutics. With the appointment, Andrew Levin will leave the board. Vor Bio is a clinical-stage biotechnology company advancing telitacicept in global Phase‑3 trials, is approved in China for multiple indications, is valued at $1.1 billion and shows a high liquidity ratio (Current Ratio 31.15) according to analysis; the stock has risen 48% over the past six months and 54% year-to-date. » Plus sur de.investing.com

Vor Bio announced that the TELIGAN phase-3 data on telitacicept in IgA nephropathy, published in the New England Journal of Medicine, showed a marked reduction in proteinuria. At week 39 the 24-hour urine protein-to-creatinine ratio fell by 58.9% versus baseline compared with 8.8% on placebo (relative difference 55.0%). eGFR remained stable with telitacicept (-1.0% vs -7.7% with placebo) and serious adverse events were less frequent than with placebo. Telitacicept is already approved in China for several autoimmune diseases and Vor Bio is advancing additional global phase-3 studies. » Plus sur de.investing.com

Vor Biopharma’s board has reset the exercise price for about 5.2 million employee options to $8.18 per share, corresponding to the closing price on 5 December 2025. The re-pricing affects options with prior prices ranging from $17.80 to $47.60 and is conditioned on continuous employment through at least 5 December 2027; early exercise remains possible at the original price. CEO Jean-Paul Kress holds 4,164,831 of the newly re-priced options; the CFO was offered cancellation of RSUs in exchange for options with a reducible price. In parallel, Vor plans a placement of 10 million common shares at $10.00 each (gross target $100m) and received an overweight rating from JPMorgan with a $43.00 price target citing potential in telitacicept. » Plus sur de.investing.com